{"product_id":"idya-bcg-matrix","title":"(IDYA) IDEAYA Biosciences, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis IDEAYA Biosciences, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. It is useful for strategy, portfolio review, and capital allocation, and this page already shows a real preview of the actual analysis. Buy the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDE196, PKC inhibitor, Phase I\/II\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDE196, also known as darovasertib, is IDEAYA Biosciences, Inc.'s lead in-house asset and the most advanced program at Phase I\/II. It targets GNAQ\/GNA11 mutations, which drive more than 90% of uveal melanoma cases, and that gives it a clear edge in precision oncology. In BCG terms, it fits as a Star because it is in a fast-growing niche and IDEAYA keeps pushing it deeper into late-stage development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDE397, MAT2A inhibitor, Phase I\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDE397 is IDEAYA Biosciences, Inc.’s first-in-class MAT2A inhibitor for MTAP-deleted solid tumors, a biomarker seen in about 15% to 25% of cancers. Its Phase I status puts it in a high-growth slot, since MTAP loss opens a large precision-oncology market. As one of IDEAYA’s lead clinical assets, it is a top-priority value driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMTAP-deletion synthetic lethality franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA’s MTAP-deletion synthetic lethality franchise is a core growth engine, with IDE397 as the lead asset and a broad path across multiple solid tumors. The company reported $748.5M in cash, cash equivalents, and marketable securities as of Q1 2024, giving it room to push this platform while clinical data stay strong. That supports a scalable leadership case, not a niche bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGNAQ and GNA11 biomarker-led oncology franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. built its PKC program around GNAQ and GNA11-driven tumors, mainly uveal melanoma, where these mutations appear in about 80% to 90% of cases. That tight biomarker filter shrinks the addressable pool, but it makes patient matching cleaner and can lift response rates if adoption keeps rising.\u003c\/p\u003e\n\u003cp\u003eIn IDEAYA’s darovasertib program, the biomarker-led design has already shown strong clinical signal in genetically defined disease, which is what a Star needs in BCG terms. The franchise looks most attractive if it keeps converting a small but high-need population into repeatable use.\u003c\/p\u003e\n\u003cp\u003eFor investors, the key test is scale, not science: high target precision, clear mutation testing, and better outcomes can support growth even in a niche market. If penetration deepens in uveal melanoma and related GNAQ\/GNA11 tumors, this could stay a Star.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e80%-90% mutation rate in uveal melanoma\u003c\/li\u003e\n\u003cli\u003eClear biomarker makes targeting easier\u003c\/li\u003e\n\u003cli\u003eNiche market, but high precision\u003c\/li\u003e\n\u003cli\u003eStar case depends on adoption growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical precision-oncology platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. treats its clinical precision-oncology platform as a Star because its synthetic lethality and biomarker selection engine can keep spawning new oncology programs, not just one asset. That matters in a pipeline-led model: each hit can feed the next wave of trials and widen the addressable market. In 2025, the platform still underpins multiple clinical-stage bets, so its growth option is bigger than any single drug.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives repeated target discovery\u003c\/li\u003e\n\u003cli\u003eUses biomarker-led patient selection\u003c\/li\u003e\n\u003cli\u003eSupports multiple pipeline programs\u003c\/li\u003e\n\u003cli\u003eFits a high-growth Star profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA’s Star Assets: Darovasertib and IDE397 Keep Growth in Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. keeps its Stars in darovasertib and IDE397: both are biomarker-led, clinical-stage, and tied to large unmet needs in precision oncology. Darovasertib targets GNAQ\/GNA11 uveal melanoma, while IDE397 targets MTAP-deleted tumors across a broader solid-tumor base. These programs still look like growth drivers, not cash cows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarovasertib\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II\u003c\/td\u003e\n\u003ctd\u003eStrong biomarker fit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDE397\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003eBroad MTAP market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eIDEAYA’s BCG Matrix maps its oncology pipeline across Stars, Question Marks, Cash Cows, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page IDEAYA Biosciences BCG Matrix that clarifies pipeline priorities for fast strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for IDEAYA Biosciences, helping investors verify assumptions quickly and make decisions with greater confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer partnership, metastatic uveal melanoma and skin melanoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.'s Pfizer partnership on metastatic uveal melanoma, skin melanoma, and other solid tumors helps fund development and supply, so it lowers IDEAYA Biosciences, Inc.'s cash burn. That makes it a cash cow in BCG terms: the asset can keep generating value while Pfizer shares trial costs and execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK strategic alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA’s strategic alliance with GlaxoSmithKline works like a cash-flow buffer: it can bring non-dilutive funding, milestone payments, and shared development costs, without IDEAYA needing a marketed product. In 2025, that matters because IDEAYA still had no product revenue, so partner-backed capital helps reduce dilution and supports pipeline spending.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCancer Research UK and University of Manchester collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.'s Cancer Research UK and University of Manchester tie-up fits Cash Cows because it offloads early PARG inhibitor discovery to outside researchers. That can cut IDEAYA's internal lab spend and preserve capital for later-stage programs. The tradeoff is modest direct revenue, but it helps build a lower-cost pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-funded clinical supply model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.’s partner-funded clinical supply model shifts drug-manufacturing and trial-supply costs onto collaborators, so IDEAYA keeps more cash for R\u0026amp;D. In precommercial biotech, that works like a cash cow because partner support lowers burn while the company still advances programs. This structure improves capital efficiency and helps preserve runway through 2025 filings and 2026 development spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners fund part of clinical supply costs\u003c\/li\u003e\n\u003cli\u003eLower burn, better cash preservation\u003c\/li\u003e\n\u003cli\u003eMore capital for pipeline development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-dilutive collaboration income stream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. leans on partner-funded deals, not product sales, so upfront cash, milestone payments, and shared R\u0026amp;D costs act like its cash cow. With no approved drugs yet, this is its closest mature cash-generating stream and helps fund oncology programs without heavy dilution. That matters because every deal can extend runway before launch revenue exists.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfronts fund early work\u003c\/li\u003e\n\u003cli\u003eMilestones add non-dilutive cash\u003c\/li\u003e\n\u003cli\u003eCost-sharing lowers burn\u003c\/li\u003e\n\u003cli\u003eNo approved drugs yet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA’s Cash Cow: Partner-Funded R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. has no approved drugs in 2025-2026, so its Cash Cows are partner deals, not product sales. Pfizer, GlaxoSmithKline, and Cancer Research UK\/University of Manchester help fund R\u0026amp;D through upfronts, milestones, and shared trial costs, which cuts burn and stretches runway. That makes partner-funded collaboration the closest steady cash source for IDEAYA Biosciences, Inc.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025-2026\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed strategic partners\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding effect\u003c\/td\u003e\n\u003ctd\u003eLower cash burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eIDEAYA Biosciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact IDEAYA Biosciences, Inc. BCG Matrix report you’ll receive after purchase. The file includes the same professional formatting, analysis, and structure shown here—no demo content or hidden changes. Once purchased, you’ll get the full version instantly for download, editing, or presentation. What you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences has 0 approved products and no commercial sales, so the Dog quadrant is effectively empty. In 2025, the Company remained clinical-stage, with value tied to pipeline assets like darovasertib rather than an installed brand. So there is no true revenue dog to classify or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 marketed oncology brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. has 0 marketed oncology brands, so there is no commercial product base to trail in a mature market. In 2025, it still had no routine product sales, which means this BCG Dogs bucket does not fit the classic low-growth, low-share profile.\u003c\/p\u003e\n\u003cp\u003eWith no launch yet, IDEAYA Biosciences, Inc. avoids the drag of an installed brand losing share. The company is still pre-commercial, so the key numbers are pipeline and cash, not marketed-brand sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 direct product revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences had $0 direct product revenue in its latest reported fiscal year, so its value still comes from pipeline programs and partnerships, not sales. There is no legacy product cash flow to cut or divest, which means this is not a \"dog\" in the classic BCG sense. The company is still pre-commercial, with cash tied to R\u0026amp;D and deal milestones, not a product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e0 mature commercial franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. still has 0 approved products and no mature commercial franchise, so there is no low-growth cash cow to defend. With 2025 revenue at $0 and no broad sales force in place, this “Dogs” bucket is effectively empty. In BCG terms, there is no cash-trap product unit here.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo approved therapy\u003c\/li\u003e\n\u003cli\u003e2025 revenue: $0\u003c\/li\u003e\n\u003cli\u003eNo commercial sales base\u003c\/li\u003e\n\u003cli\u003eNo cash-cow asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e0 dividend or buyback cash engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. showed a 0 dividend and 0 buyback cash return profile in FY2025, which fits a clinical-stage biotech that keeps capital inside research and development. It is not a mature cash-distribution company, so the dog quadrant is structurally absent. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 dividend payout in FY2025\u003c\/li\u003e\n\u003cli\u003e0 share repurchases disclosed\u003c\/li\u003e\n\u003cli\u003eCash stayed focused on R and D\u003c\/li\u003e\n\u003cli\u003eNo steady product cash to return\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters because IDEAYA’s 2025 spending priority was pipeline buildout, not shareholder cash yield. In BCG terms, its low payout and reinvestment profile signal growth-stage risk, not a “dog” cash drag. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo Dogs, Just Pipeline and Cash Preservation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. has no approved products, no commercial sales, and FY2025 revenue of $0, so the Dogs quadrant is effectively empty. With no legacy brand to defend or divest, the business stays focused on pipeline R\u0026amp;D and cash preservation. There is no true low-share, low-growth product unit to classify as a dog.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial sales\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePARG inhibitor, preclinical to early-stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.’s PARG inhibitor is a preclinical-to-early-stage synthetic lethality bet aimed at biomarker-defined tumors, so it fits the Question Mark bucket. The asset still lacks clinical proof, so market share is uncertain even if the biology works. That mix of high upside and high failure risk is classic Question Mark behavior.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePol Theta inhibitor, BRCA and HRD tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.’s Pol Theta inhibitor targets BRCA and other homologous recombination deficiency tumors, a large and biologically appealing market, with HRD seen in about 20% to 25% of solid tumors. But the program is still early, so clinical proof is limited and the value case is not yet de-risked. It stays a Question Mark until stronger efficacy and safety data can show it can become a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWRN inhibitor, MSI-H tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is advancing a WRN inhibitor for microsatellite instability-high, or MSI-H, tumors, a biomarker found in about 3% to 5% of solid tumors. The target is clear, but the asset is still in development, so it has no commercial proof yet. Until clinical data show durable response and safety, this program stays in question-mark territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdditional synthetic lethality discovery programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. keeps pushing beyond its lead assets by adding new synthetic lethality targets, and that gives it pipeline optionality. These programs fit the question-mark box because they are still unproven until human data show response and durability. They also draw on R and D capital before payback is clear.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upside, low proof.\u003c\/li\u003e\n\u003cli\u003eR and D spend stays front-loaded.\u003c\/li\u003e\n\u003cli\u003eSuccess depends on trial readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew biomarker-defined oncology indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. treats new biomarker-defined oncology indications as a growth bet: each new genetically selected tumor group can open a large market, but share stays at 0% until Phase 1\/2 data show real clinical traction. That is why this sits in the BCG Question Marks bucket: high upside, but still unproven. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, no current share\u003c\/li\u003e\n\u003cli\u003eClinical data drives adoption\u003c\/li\u003e\n\u003cli\u003eExecution risk stays elevated\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA’s Early Bets Target Big Biomarker Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.’s question marks are still early, high-upside bets with no commercial share yet. PARG, POLQ, and WRN programs target biomarker-defined tumors, but each still needs Phase 1\/2 proof before value can re-rate. MSI-H tumors are only about 3% to 5% of solid tumors, while HRD is about 20% to 25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eState\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePARG\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003eNo clinical proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePOLQ\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003eHRD 20% to 25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWRN\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003eMSI-H 3% to 5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234491441417,"sku":"idya-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/idya-bcg-matrix.webp?v=1785721645","url":"https:\/\/dcfanalyst.com\/products\/idya-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}